Notice of Results
31 August 2022
Medica Group Plc
Notice of Interim Results
Medica Group Plc (LSE: MGP, "Medica", the "Company" or the "Group"), an international provider of high-quality telemedicine services, announces that, following the announcement in the Trading Update on 26 July 2022, the Company now intends to announce its interim results for the six months ended 30 June 2022 on Tuesday 27 September 2022.
A presentation for analysts will be held at 9.00 am on that day at the offices of Numis at 45 Gresham St, London, EC2V 7BF.
For further information, please contact:
|
Medica Group Plc: Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer
|
+44 (0)33 33 111 222
|
|
FTI Consulting Victoria Foster Mitchell Sam Purewal
|
+44 (0)20 3727 1000 |
|
Liberum (Joint Broker) Phil Walker Richard Lindley
|
+44 (0)20 3100 2000 |
|
Numis (Joint Broker) Freddie Barnfield Duncan Monteith Euan Brown
|
+44 (0)20 7260 1000
|
About Medica Group PLC
Medica (LSE:MGP) is an international provider of high-quality telemedicine services. It is the market leader in teleradiology in the UK and Ireland, working with more than 100 NHS Trusts and HSE hospitals in Ireland, in addition to private hospitals, insurance groups and diagnostic imaging companies. Its network of consultant radiologists, radiographers and specialist doctors interpret and report MRI, CT, ultrasound and X-ray images on behalf of healthcare providers, using Medica's bespoke, secure technology platform for fast and responsive delivery. The Company's core services include NightHawk, an urgent, out-of-hours offering available to clients 24/7 with dedicated pathways for stroke and major trauma, and Elective, for routine reporting.
In Ireland, Medica carries out patient scanning, as well as reporting, and runs a diabetic retinopathy screening programme for the National Screening Service. Through its US business, RadMD, Medica provides global pharmaceutical and biotech companies, as well as contract research organisations with specialist imaging services for clinical trials.
For more information, please visit: www.medicagroupplc.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 3 hours ago Judges Scientific
- 4 hours ago Mitie Group
- 5 hours ago NCC Group
- 5 hours ago Worldwide Healthcare Trust
- 6 hours ago JpMorgan China Growth & Income